Pulmonary Cell News Volume 11.16 | Apr 28 2022

    By
    Ishira
    -
    0
    43







    2022-04-28 | PULCN 11.16


    Pulmonary Cell News by STEMCELL Technologies
    Vol. 11.16 – 28 April, 2022
    TOP STORY

    Targeted Drug/Gene/Photodynamic Therapy via a Stimuli-Responsive Dendritic Polymer-Based Nano-Cocktail for Treatment of EGFR-TKI-Resistant Non-Small Cell Lung Cancer

    Scientists suggested that a stimuli-responsive dendritic polymer-based nano-cocktail therapy may provide a promising approach for the treatment of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistant NSCLC.
    [Advanced Materials]

    Abstract
    ON987CXN-may-728x90-2022
    PUBLICATIONSRanked by the impact factor of the journal

    SARS-CoV-2 Infection of Human-Induced Pluripotent Stem Cells-Derived Lung Lineage Cells Evokes Inflammatory and Chemosensory Responses by Targeting Mitochondrial Pathways

    Researchers showed that SARS-CoV-2 readily infected and replicated in human-induced pluripotent stem cell-derived proximal airway cells, distal alveolar cells, and lung progenitors.
    [Journal of Cellular Physiology]

    Full Article

    Exosomes Derived from Hypoxia-Induced Alveolar Epithelial Cells Stimulate Interstitial Pulmonary Fibrosis through a HOTAIRM1-Dependent Mechanism

    The authors investigated the therapeutic potential of HOTAIRM1 transferred by alveolar epithelial cell-derived exosomes in interstitial pulmonary fibrosis and the potential molecular mechanisms.
    [Laboratory Investigation]

    Abstract

    SETDB1 Fuels the Lung Cancer Phenotype by Modulating Epigenome, 3D Genome Organization and Chromatin Mechanical Properties

    Investigators demonstrated that a loss-of-function mutation of the major histone lysine methyltransferase SETDB1 possessing oncogenic activity in lung cancer cells led to broad changes in the overall architecture and mechanical properties of the nucleus through genome.
    [Nucleic Acids Research]

    Full Article
    Graphical Abstract

    CRL2KLHDC3 Mediates p14ARF N-terminal Ubiquitylation Degradation to Promote Non-Small Cell Lung Carcinoma Progression

    Kelch domain containing 3 (KLHDC3) shortage significantly increased the sensitivity of lung cancer cells to epidermal growth factor receptor-targeted drugs, providing an alternative explanation for the development of Gefitinib and Osimertinib resistance in NSCLC therapy.
    [Oncogene]

    Abstract

    HIF1α-SP1 Interaction Disrupts the Circ-0001875/miR-31-5p/SP1 Regulatory Loop under a Hypoxic Microenvironment and Promotes Non-Small Cell Lung Cancer Progression

    High-throughput RNA sequencing was performed to identify significantly expressed circular RNAs in NSCLC tissues. The functions of circ-0001875 in NSCLC cells were investigated in vitro and in vivo.
    [Journal of Experimental & Clinical Cancer Research]

    Full Article

    SHANK1 Facilitates Non-Small Cell Lung Cancer Processes through Modulating the Ubiquitination of Klotho by Interacting with MDM2

    Scientists reported that the expression of SHANK1 was upregulated in NSCLC, and was correlated with clinic pathological characteristics of NSCLC.
    [Cell Death & Disease]

    Full Article

    TCRP1 Activated by Mutant p53 Promotes NSCLC Proliferation via Inhibiting FOXO3a

    Researchers found that tongue cancer resistance-associated protein (TCRP1) was increased in p53-mutant NSCLC, comparing to that in NSCLC with wild type p53.
    [Oncogenesis]

    Full Article

    Protective Autophagy Decreases Lorlatinib Cytotoxicity through Foxo3a-Dependent Inhibition of Apoptosis in NSCLC

    The efficacy of chloroquine in combination with lorlatinib in anaplastic lymphoma kinase-positive NSCLC cells in vitro and in vivo was assessed using CCK-8, colony formation, immunofluorescence staining, flow cytometry analysis, western blot analysis, and xenograft implantation.
    [Cell Death Discovery]

    Full Article

    Combining Plasma Extracellular Vesicle Let-7b-5p, miR-184 and Circulating miR-22-3p Levels for NSCLC Diagnosis and Drug Resistance Prediction

    Targeting Hsa-miR-22-3p and Hsa-miR-184 desensitized EGFR-mutated NSCLC cells to Osimertinib.
    [Scientific Reports]

    Full Article

    Deletion of TRIB3 Disrupts the Tumor Progression Induced by Integrin αvβ3 in Lung Cancer

    Researchers suggested that integrin αvβ3 could efficiently promote lung cancer cell proliferation and stem-like phenotypes in a tribbles homolog 3 (TRIB3) dependent manner.
    [BMC Cancer]

    Full Article

    Activation of circ_0072088/miR-1261/PIK3CA Pathway Accelerates Lung Adenocarcinoma Progression

    Circ_0072088-dependent regulation of miR-1261/PIK3CA was important for cell proliferation, migration, and invasion during the tumorigenesis and progression of lung adenocarcinoma.
    [Thoracic Cancer]

    Full Article
    Request your free copy of the 'Growing Organoids from Stem Cells' Wallchart
    REVIEWS

    Long Non-Coding RNAs and Exosomal lncRNAs: Potential Functions in Lung Cancer Progression, Drug Resistance and Tumor Microenvironment Remodeling

    The authors discuss regulation of lncRNAs by anti-cancer drugs and genetic tools as well as the role of these factors in therapy response of lung cancer cells.
    [Biomedicine & Pharmacotherapy]

    Full ArticleGraphical Abstract

    Biocomposite-Based Nanostructured Delivery Systems for Treatment and Control of Inflammatory Lung Diseases

    Scientists deliver up-to-date research in nanostructured therapies in inflammatory lung diseases with an emphasis on biocomposite-based nanoparticles.
    [Nanomedicine]

    Abstract
    INDUSTRY AND POLICY NEWS

    ImmunityBio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer

    ImmunityBio, Inc. announced that the first participants have been enrolled in a study that is part of an 800-site master protocol trial for NSCLC. The Lung Cancer Master Protocol trial (Lung-MAP) includes a study of Anktivaâ„¢ plus Keytruda versus investigator choice of standard-of-care chemotherapy in patients with NSCLC.
    [ImmunityBio, Inc.]

    Press Release

    Novartis Receives Positive CHMP Opinion for Tabrecta® for Patients with METex14 Advanced Non-Small Cell Lung Cancer

    Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion and recommended granting marketing authorization of Tabrecta® as a monotherapy for the treatment of adults with advanced NSCLC.
    [Novartis]

    Press Release

    OncoC4 Announces Fast Track Designation Granted by the US FDA for ONC-392 Monotherapy in PD(L)1-Resistant NSCLC

    OncoC4, Inc. announced that the US FDA has granted Fast Track designation to ONC-392, the company’s next-gen anti-CTLA-4 monoclonal antibody as a single agent for the treatment of patients with metastatic non-small cell lung carcinoma (NSCLC) who have had disease progression on prior anti-PD-(L)1 therapy.
    [OncoC4, Inc.]

    Press Release
    FEATURED EVENT

    Channels in Context: Structure and Function of Ion Channels in Macromolecular Complexes and Native Cells

    September 7 – 11, 2022
    Woods Hole, Massachusetts, United States

    > See All Events

    JOB OPPORTUNITIES

    Research Fellow – Respiratory Genomics

    Mayo Clinic – Scottsdale, Arizona, United States

    Senior Research Scientist – Pulmonology

    Gilead Sciences, Inc. – Foster City, California, United States

    Research Chair – Lung Regenerative Medicine

    McGill University – Montreal, Quebec, Canada

    Postdoctoral Fellow – Resistance in Small Cell Lung Cancer

    Medical Center Cologne – Cologne, Germany

    Postdoctoral Scholar – Translational Lung Cancer

    The Ohio State University – Columbus, Ohio, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Pulmonary Cell News Twitter